279 related articles for article (PubMed ID: 30799657)
1. Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins.
Liu XQ; Xin HY; Lyu YN; Ma ZW; Peng XC; Xiang Y; Wang YY; Wu ZJ; Cheng JT; Ji JF; Zhong JX; Ren BX; Wang XW; Xin HW
Drug Deliv; 2018 Nov; 25(1):1950-1962. PubMed ID: 30799657
[TBL] [Abstract][Full Text] [Related]
2. Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses.
Bucurescu S
Acta Pharm; 2010 Dec; 60(4):407-13. PubMed ID: 21169133
[TBL] [Abstract][Full Text] [Related]
3. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
Menotti L; Avitabile E
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins.
Eing BR; Kühn JE; Braun RW
J Med Virol; 1989 Jan; 27(1):59-65. PubMed ID: 2466100
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
[TBL] [Abstract][Full Text] [Related]
6. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
[TBL] [Abstract][Full Text] [Related]
7. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
Conner J; Braidwood L; Brown SM
Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
[TBL] [Abstract][Full Text] [Related]
8. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.
Muik A; Stubbert LJ; Jahedi RZ; Geiβ Y; Kimpel J; Dold C; Tober R; Volk A; Klein S; Dietrich U; Yadollahi B; Falls T; Miletic H; Stojdl D; Bell JC; von Laer D
Cancer Res; 2014 Jul; 74(13):3567-78. PubMed ID: 24812275
[TBL] [Abstract][Full Text] [Related]
9. The molecular basis of herpesviruses as oncolytic agents.
Menotti L; Campadelli-Fiume G; Nanni P; Lollini PL; De Giovanni C
Curr Pharm Biotechnol; 2012 Jul; 13(9):1795-803. PubMed ID: 21740356
[TBL] [Abstract][Full Text] [Related]
10. Characterization of epitopes on the rabies virus glycoprotein by selection and analysis of escape mutants.
Fallahi F; Wandeler AI; Nadin-Davis SA
Virus Res; 2016 Jul; 220():161-71. PubMed ID: 27132040
[TBL] [Abstract][Full Text] [Related]
11. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Herpes Simplex Virus-Based Therapies for Cancer.
Aldrak N; Alsaab S; Algethami A; Bhere D; Wakimoto H; Shah K; Alomary MN; Zaidan N
Cells; 2021 Jun; 10(6):. PubMed ID: 34207386
[TBL] [Abstract][Full Text] [Related]
13. Probing Zika Virus Neutralization Determinants with Glycoprotein Mutants Bearing Linear Epitope Insertions.
Chambers MT; Schwarz MC; Sourisseau M; Gray ES; Evans MJ
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976678
[TBL] [Abstract][Full Text] [Related]
14. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
[TBL] [Abstract][Full Text] [Related]
15. Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus.
Forrester AJ; Sullivan V; Simmons A; Blacklaws BA; Smith GL; Nash AA; Minson AC
J Gen Virol; 1991 Feb; 72 ( Pt 2)():369-75. PubMed ID: 1704412
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
17. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
18. The herpes simplex virus type 1 US7 gene product is a 66K glycoprotein and is a target for complement-dependent virus neutralization.
Sullivan V; Smith GL
J Gen Virol; 1988 Apr; 69 ( Pt 4)():859-67. PubMed ID: 2833569
[TBL] [Abstract][Full Text] [Related]
19. High therapeutic potential for systemic delivery of a liposome-conjugated herpes simplex virus.
Shikano T; Kasuya H; Sahin TT; Nomura N; Kanzaki A; Misawa M; Nishikawa Y; Shirota T; Yamada S; Fujii T; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Curr Cancer Drug Targets; 2011 Jan; 11(1):111-22. PubMed ID: 21062239
[TBL] [Abstract][Full Text] [Related]
20. Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) by recombinant vaccinia virus: neutralization of HSV-1 infectivity with anti-gG antibody.
Sullivan V; Smith GL
J Gen Virol; 1987 Oct; 68 ( Pt 10)():2587-98. PubMed ID: 2822841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
